By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring.
Teva Pharmaceutical Industries Ltd. et al. v. Apotex, Inc. et al.
3:07-cv-04897; filed October 10, 2007 in the District Court of New Jersey
Declaratory judgment of infringement of U.S. Patent Nos. 6,699,997 ("Carvedilol," issued March 2, 2004), 6,710,184 ("Crystalline Solids of Carvedilol and Processes for Their Preparation," issued March 23, 2004), 7,056,942 ("Carvedilol," issued June 6, 2006), and 7,126,008 (same title, issued October 24, 2006) based on Apotex's filing of an ANDA to manufacture and sell a generic version of GSK's Coreg® (carvedilol, used to treat congestive heart failure). View the complaint here.
Cornerstone BioPharma, Inc. et al. v. Vision Pharma, LLC et al.
5:07-cv-00389; filed October 8, 2007 in the Eastern District of North Carolina
Infringement of U.S. Patent No. 6,270,796 ("Antihistamine/Decongestant Regimens for Treating Rhinitis," issued August 7, 2001) based on defendants' manufacture and sale of VisRx, allegedly a "generic" version of Cornerstone's AlleRx® Dose Pack Products (used to treat allergies and symptoms of the common cold). View the complaint here.
Celgene Corporation et al. v. Intellipharmaceutics Corp.
3:07-cv-04854; filed October 5, 2007 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 5,908,850 ("Method of Treating Attention Deficit Disorders with d-Threo Methylphenidate," issued June 1, 1999), 6,355,656 ("Phenidate Drug Formulations Having Diminished Abuse Potential," issued March 12, 2002, with a reexamination certificate issued March 27, 2007), 6,528,530 ("Phenidate Drug Formulations Having Diminished Abuse Potential," issued March 4, 2003), 5,837,284 ("Delivery of Multiple Doses of Medications," issued November 17, 1998), and 6,635,284 (same title, issued October 21, 2003), all licensed exclusively to Novartis in certain fields of use, following a paragraph IV certification as part of Intellipharmaceutics' filing of an ANDA to manufacture a generic version of Novartis' Focalin XR® (extended release dexmethylphenidate hydrochloride, used to treat attention deficit hyperactivity disorder). View the complaint here.
Sanofi-Aventis et al. v. Mylan Pharmaceuticals Inc.
1:07-cv-00139; filed October 5, 2007 in the Northern District of West Virginia
Infringement of U.S. Patent Nos. 4,661,491 ("Alfuzosine Compositions and Use," issued April 28, 1987) and 6,149,940 ("Tablet with Controlled Release of Alfuzosine Chlorhydrate," issued November 21, 2000) following a paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Sanofi-Aventis' Uroxatral® (alfuzosin hydrochloride, used to treat benign prostatic hyperplasia). View the complaint here.
Celgene Corporation et al. v. KV Pharmaceutical Company
2:07-cv-04819; filed October 4, 2007 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 5,837,284 ("Delivery of Multiple Doses of Medications," issued November 17, 1998) and 6,635,284 (same title, issued October 21, 2003) (both assigned to Celgene and licensed exclusively to Novartis in certain fields of use) following a paragraph IV certification as part of KV's filing of an ANDA to manufacture a generic version of Novartis' Ritalin® LA (methylphenidate hydrochloride extended release capsules, used to treat attention deficit hyperactivity disorder/attention deficit disorder). View the complaint here.
Eli Lilly and Company v. Synthon Laboratories, Inc.
2:07-cv-00450; filed October 3, 2007 in the Eastern District of Virginia
Infringement of U.S. Patent No. 5,658,590 ("Treatment of Attention-Deficit/ Hyperactivity Disorder," issued August 19, 1997) following a paragraph IV certification as part of Synthon's filing of an ANDA to manufacture a generic version of Lilly's Strattera® (atomoxetine hydrochloride, used to treat attention-deficit/hyperactivity disorder). View the complaint here.
Adams Respiratory Therapeutics, Inc. et al. v. Perrigo Company et al.
1:07-cv-00993; filed October 2, 2007 in the Western District of Michigan
Infringement of U.S. Patent No. 6,372,252 ("Guaifenesin Sustained Release Formulation and Tablets," issued April 16, 2002) following a paragraph IV certification as part of Perrigo's filing of an ANDA to manufacture a generic version of Adams' Mucinex® (guaifenesin, used to treat chest congestion). View the complaint here.
Comments